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Abstract
Background—Cross-sectional studies of children with prevalent nephrotic syndrome (NS) have 
shown 25-vitamin D (25(OH)D) deficiency rates of 20–100 %. Information on 25(OH)D status in 
incident patients or following remission is limited. This study aimed to assess 25(OH)D status of 
incident idiopathic NS children at presentation and longitudinally with short-term observation.
Methods—Multicenter longitudinal study of children (2–18 years old) from 14 centers across the 
Midwest Pediatric Nephrology Consortium with incident idiopathic NS. 25(OH)D levels were 
assessed at diagnosis and 3 months later.
Results—Sixty-one children, median age 5 (3, 11) years, completed baseline visit and 51 
completed second visit labs. All 61 (100 %) had 25(OH)D<20 ng/ml at diagnosis. Twenty-seven 
(53 %) had 25(OH)D<20 ng/ml at follow-up. Fourteen (28 %) children were steroid resistant. 
Univariate analysis showed that children prescribed vitamin D supplements were less likely to 
have 25(OH)D deficiency at follow-up (OR 0.2, 95 % CI 0.04, 0.6). Steroid response, age, and 
season did not predict 25(OH)D deficiency. Multivariable linear regression modeling showed 
higher 25(OH)D levels at follow-up by 13.2 ng/ml (SE 4.6, p<0.01) in children supplemented with 
vitamin D.
Conclusions—In this incident idiopathic NS cohort, all children at diagnosis had 25(OH)D 
deficiency and the majority continued to have a deficiency at 2–4 months. Supplemental vitamin 
D decreased the odds of 25(OH)D deficiency at follow-up, supporting a role for supplementation 
in incident NS.
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Introduction
Idiopathic nephrotic syndrome (NS) is one of the most common forms of kidney disease in 
children, affecting 15 to 20 per 100,000 children, often with a frequently remitting and 
relapsing course [1, 2]. In studies of pediatric patients with prevalent primary and secondary 
NS, 25-hydroxyvitamin D (25(OH)D) deficiency ranges from 20 to 100 % in patients who 
were surveyed at different points during their disease [3–7], which contrasts with rates of 9–
18 % in the general pediatric population [8–10]. Initially, these abnormalities were thought 
to be transient in nature and resolved with remission, but recent data suggests that 25(OH)D 
deficiency persists despite achieving remission [11].
Abnormal vitamin D metabolism in idiopathic NS is multi-factorial, with contributions from 
losses of both vitamin D binding protein and 25(OH)D in the urine [12, 13]. The urinary 
losses of vitamin D binding protein may be secondary to proteinuria, overwhelming the 
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proximal tubule reabsorption via megalin and cubilin pathways [14]. Deficiency in 
25(OH)D may lead to hypocalcemia, hyperparathyroidism, and diminished bone mineral 
density/content. Vitamin D deficiency has also been associated with multiple systemic 
effects including elevated blood pressure [15, 16], metabolic syndrome, cardiovascular 
disease [17], anemia [18], and impaired immune system regulation [19].
Complicating the impact of 25(OH)D deficiency on the bones in children with NS is the 
repeated exposure to glucocorticoids. The initial treatment at diagnosis and with each 
relapse exceeds the 5 mg/day of prednisone shown to cause osteoporosis in adults [20]. This 
has led to an increased interest in the impact of pediatric NS on the bone metabolism in 
developing children. Children with NS have been shown to have decreased bone 
mineralization, although the mechanism was not defined [21, 22]. Furthermore, studies in 
adult survivors of steroid-sensitive minimal change disease show persistent bone 
abnormalities [23]. These findings have led to an increased interest in differing strategies 
and trials around supplementation of calcium and vitamin D in children with NS [24–26].
There is a significant gap in the knowledge about 25(OH)D levels in patients with incident 
NS and the effect of disease course on these levels following initial treatment. To date, there 
has not been a study evaluating 25(OH)D deficiency in children with prospective 
observation beginning with the initial diagnosis of NS.
This multicenter international prospective longitudinal study aimed to: (1) describe the 
prevalence of 25(OH)D deficiency at presentation with NS, (2) describe the prevalence of 
continued 25(OH)D deficiency at 3 months following initial treatment, and (3) to investigate 
the association of treatment response and supplementation with 25(OH)D deficiency at 
follow-up. We hypothesized that 25(OH)D deficiency would be common at presentation and 
at 3-month follow-up in children with incident NS and that steroid response pattern and 
supplementation with vitamin D would predict deficiency at follow-up.
Methods
We performed a prospective observational study of children recruited from the participating 
centers of the Midwest Pediatric Nephrology Consortium with incident NS. This study 
enrolled 61 pediatric patients from 14 participating member institutions in North America 
(see author affiliations). The inclusion criteria were age 2–18 years, incident NS with ≤ 14 
days of corticosteroid treatment, urine protein/creatinine> 2 mg/mg or urinalysis≥2+protein 
and edema. We excluded patients with evidence of a disease process other than idiopathic 
NS, including hypocomplementemia, positive antinuclear antibody (>1:80) or systemic 
vasculitis.
Enrolled children underwent two study visits. The first study visit was within 2 weeks of 
corticosteroid initiation. The second study visit was 2–4 months following enrollment, 
which was timed to coincide with the completion of a standard 12-week corticosteroid 
treatment for new-onset idiopathic NS. The treatment regimen was at the discretion of the 
treating physician. At each visit, data collection included race, season, geographical 
location, medications, response to therapy, and local laboratory data when available 
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(including electrolytes and urine). Relapse, remission, and steroid dependence vs. resistance 
were defined according to published standards [2]. The seasons were defined as winter 
(12/21–3/20), spring (3/21–6/20), summer (6/21–9/20), and fall (9/21–12/20). Patient 
locations in Michigan, Ohio, Ontario, Iowa, Missouri, Wisconsin, and Utah were classified 
as North. Patient locations in North Carolina, South Carolina, Kentucky, Georgia, and 
Louisiana were classified as South. Intact parathyroid hormone (iPTH), 25(OH)D and 1,25-
hydroxyvitamin D (1, 25(OH)D) were obtained at both study visits and measured at a central 
laboratory.
Blood samples were frozen at −80 °C and shipped to the clinical laboratory at the University 
of Michigan. The 25(OH)D levels were measured using a DiaSorin chemiluminescence 
assay with a laboratory reference range of 25–100 ng/ml. The 1,25(OH)D levels were 
measured using the DiaSorin radioimmunoassay with normal range of 18–72 pg/ml. Intact 
PTH (iPTH) levels were assessed using immunometric chemiluminescence with normal 
values of 10–65 pg/ml. There were inadequate samples for analysis of iPTH (one baseline; 
one return visit) and 1,25 (OH) D (seven baseline; five return visit). When local electrolytes 
were not available, samples were run centrally. The vitamin D test results were reported to 
the providers who were subsequently allowed to modify patient care at their discretion.
Outcome
The primary outcome of interest was vitamin D deficiency as measured by the 25(OH)D 
levels in the blood, which is reflective of total body stores [27]. The analysis was performed 
utilizing two cut-offs for inadequate 25(OH)D levels< 20 ng/ml and<30 ng/ml [8, 10].
Statistical analysis
Characteristics of baseline and follow-up samples were described using median (inter-
quartile range) for continuous variables and frequency (percentage) for categorical variables. 
The relationship between 25(OH)D, 1,25(OH)2D and iPTH at baseline and follow-up were 
tested using Pearson correlation coefficients. Possible predictors of the two dichotomous 
outcome variables (25(OH)D<20 ng/ml and <30 ng/ml) were assessed using an 
unconditional binary logistic regression. In a separate analysis, we tested for differences in 
25(OH)D levels as a continuous variable using linear regression. We tested the following 
covariates: age, sex, season, race, location (North vs. South), steroid response pattern, and 
vitamin D supplementation. All analyses were conducted using SAS software (SAS Institute 
Inc. Cary, NC, USA).
Results
Sixty-one patients with incident NS were enrolled and completed the baseline study visit. 
The median age at enrollment was 5 (3, 11) years. Twenty-one patients (34 %) were enrolled 
in the winter and 17 patients (28 %) were enrolled from states in the North. Seventeen 
patients (28 %) were taking prednisone and four patients (7 %) were taking vitamin D 
supplements at study enrollment. The median 25(OH)D level at enrollment was 9 (7, 11) 
ng/ml. All 61 patients had 25(OH)D levels<20 ng/ml at enrollment. Twenty-eight (47 %) of 
60 patients with measured iPTH values had an elevated iPTH level (>65 pg/ml) at the 
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baseline visit. Nineteen (35 %) of 54 patients with measured 1,25(OH)D level had a low 1, 
25(OH)D level (<18 pg/ml) at the baseline visit. There was no correlation between corrected 
calcium and 25(OH)D, 1, 25(OH)D or iPTH at baseline. Table 1 summarizes patient 
demographics and laboratory characteristics at enrollment.
Fifty-one children completed the second visit (84 % retention rate). The median time 
between visits was 2.6 (2.1, 3.4) months. The second visit most commonly occurred in the 
summer (n=17, 33 %). Fourteen patients (28 %) were steroid resistant at the follow-up visit 
and 16 patients were in relapse at follow-up. The median 25(OH)D level at follow-up was 
19 (10, 25) ng/ml. Seventeen patients (33 %) were receiving vitamin D supplementation at 
follow-up. Twenty-seven patients (53 %) had 25(OH) D levels<20 ng/ml and 43 patients (84 
%) had 25(OH) D levels<30 ng/ml. Fifteen (30 %) of 50 patients with measured iPTH 
values had an elevated intact PTH level (>65 pg/ml) at the follow-up. One patient (2 %) of 
46 patients with measured 1,25(OH)D level had a low 1,25(OH)D level (<18 pg/ml) at 
follow-up. The patient demographics and laboratory characteristics at the follow-up visit are 
presented in Table 2.
We evaluated the association of 25(OH)D deficiency with abnormalities in 1,25(OH)D and 
iPTH levels. At baseline, all patients had 25(OH)D deficiency, 47 % had an elevated iPTH 
level and 35 % had a low 1,25(OH)D level. At baseline there were no significant 
correlations between 25(OH)D levels and 1,25(OH)D (r=−0.02, p=0.89) or iPTh levels (r=
−0.03, p= 0.81). At follow-up, 50 patients had iPTH values available for evaluation and 27 
of these patients (54 %) had 25(OH)D< 20 ng/ml and 43 patients (86 %) had 25(OH) D 
levels< 30 ng/ml. Elevated iPTH levels were present in 12 patients (44 %) and 14 (33 %) of 
the patients with 25(OH)D<20 ng/ml and<30 ng/ml, respectively. At follow-up, 46 patients 
had 1, 25(OH)D level values measured and 25 of these patients (54 %) had 25(OH)D<20 
ng/ml and 39 patients (85 %) had 25(OH) D levels<30 ng/ml. Low 1,25(OH)D levels were 
present in 0 patients and 1 patient with 25(OH)D<20 ng/ml and<30 ng/ml, respectively. At 
follow-up, there were no significant correlations between 25(OH)D levels and 1,25(OH)D 
(r=0.13, p=0.39) or iPTh levels (r=−0.01, p=0.93). For patients that were in remission at 
follow-up, the correlation between 25(OH)D levels with 1,25(OH)D (r=0.33, p=0.06) and 
iPTh levels approached significance (r=−0.34, p=0.05). For patients that were in relapse at 
follow-up, there was no significant correlation between 25(OH)D levels and 1,25(OH)D (r=
−0.17, p=0.57), but there was a correlation with iPTh levels (r=0.54, p=0.03).
Table 3 shows the univariate analysis describing the association between patient 
characteristics and 25(OH)D deficiency at the follow-up visit as defined by 25(OH)D<20 
ng/ml. When utilizing a definition of<20 ng/ml, male gender and black race were associated 
with increased odds of 25(OH)D deficiency. Vitamin D supplementation at follow-up and 
enrollment from sites in the North were protective against deficiency in our cohort. The 
median 25(OH) levels were not significantly different between patients that were 
supplemented with vitamin D and those that were not (p=0.62). Steroid resistance was not 
associated with 25(OH)D deficiency. For participants that had a urine protein-to-creatinine 
ratio available at the second visit (n=33), the urine protein-to-creatinine ratio was not 
associated with 25(OH)D deficiency. Children from Northern institutions were more likely 
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to be supplemented with vitamin D (57 vs. 24 %, p=0.03). Children from Northern 
institutions were not more likely to have visits in the summer months (p=0.22).
In multivariable analysis, linear regression modeling showed higher 25(OH)D levels at 
follow-up by 11.5 ng/ml (SE 4.9, p=0.02) in children residing in the North (compared to 
those in the South) and by 13.2 ng/ml (SE 4.6, p<0.01) in children supplemented with 
vitamin D (compared to those who were not supplemented). A sensitivity analysis was 
performed with the addition of serum albumin to the final linear regression model, which 
showed that the serum albumin level did not predict 25(OH)D levels (β=3.2, SE 2.3, 
p=0.17), but children in the North (β=10.4, SE 4.9, p=0.04) and those supplemented with 
vitamin D (β=13.4, SE 4.6, p<0.01) continued to have higher 25(OH)D levels. Factors that 
were not predictive of 25(OH)D deficiency at the follow-up visit included: 25(OH)D level at 
the initial visit, age, male, season, black race, and steroid resistance.
Discussion
This is the largest multi-center study to date in North American children with incident 
idiopathic NS evaluating 25(OH)D deficiency and the first study to prospectively follow 
25(OH)D levels from diagnosis in this patient population. Here we demonstrate that 
25(OH)D deficiency is universal at diagnosis and 25(OH)D deficiency persists at follow-up 
in a significant number of patients. We also show that children receiving vitamin D 
supplementation at follow-up were less likely to have low 25(OH)D levels during that visit.
There has been a long-standing recognition that children with active NS are prone to the 
development of 25(OH)D deficiency. Freundlich et al. began to explore 25(OH)D deficiency 
in 1985 in 16 children with active NS, showing levels< 20 ng/ml in all children [4]. This 
group extended these findings in a cohort of 58 children with prevalent disease followed 
during relapses and remissions, revealing that children in relapse had a mean 25(OH)D level 
of 9 ng/ml and during remission these levels improved to a mean of 30 ng/ml [3]. Huang et 
al. reported similar findings of normalized 25(OH)D levels during remission in 25 children 
with prevalent NS [28]. These data suggested that 25(OH)D deficiency in this population 
may be transient. Since that time, there has been an increasing amount of data suggesting 
that 25(OH)D levels may not completely normalize when children go into remission [6, 11, 
29]. In 2005, Weng et al. evaluated 25(OH)D levels in children with NS in remission 
showing that over 90 % had 25(OH)D<30 ng/ml and 68 % had levels<20 ng/ml [6]. Our 
findings are consistent with the previous literature demonstrating 25(OH)D deficiency in 
100 % of our cohort of children with incident NS with a median 25(OH)D level of 9 (7, 11) 
ng/ml. Furthermore, for the first time we report data obtained from follow-up of the 
25(OH)D level prospectively after diagnosis in children with idiopathic NS. We show that 
abnormalities in 25(OH)D levels persist, with 53 % of children with 25(OH)D levels<20 
mg/dl and 84 %<30 mg/dl at a median follow-up of 2.6 months after diagnosis.
In the last decade, there has been increased interest in the prevalence of 25(OH)D deficiency 
in pediatric patients. In recent reports from the National Health and Nutrition Examination 
Survey (NHANES), the prevalence of 25(OH)D abnormalities in healthy children across 
America has been assessed. These reports show a high prevalence of 25(OH)D levels<20 
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ng/ml of 14–18 % [9, 10]. The rates become even more profound when one considers the 
prevalence of deficiency with a definition of <30 ng/ml of 61 % in the general US pediatric 
population [8]. In this context, our data highlight the persistent abnormalities in 25(OH)D 
levels in children with NS following diagnosis. Past reports of children with NS in North 
America were often single center in nature and it was difficult to generalize these findings or 
compare them to datasets such as NHANES. We extend these findings by providing the 
most geographically diverse population of children with NS in North America reported to 
date. Indeed, our data suggest that abnormalities in 25(OH)D levels persist and occur at a 
greater frequency than would be expected in the general population.
The increased interest in the prevalence of 25(OH)D deficiency in children with NS parallels 
an increased interest in the impact of NS and its treatment on bone development in these 
children. This is of particular interest given that a daily dose of systemic steroids as low as 5 
mg per day has been shown to contribute to osteoporosis in adults [20]. This is of concern in 
pediatric patients following a new diagnosis of NS where steroid treatment protocols exceed 
the dose at which adult osteoporosis risk increases with repeated exposures to steroids 
during subsequent relapses [1, 2]. Given this information, there has been renewed interest in 
the impact of childhood NS on the developing bones in children. When appropriate 
corrections for body size are employed, the literature has been consistent on documenting a 
negative impact of steroid exposure on bone health in children with NS [21, 22]. Studies 
utilizing bone biopsy data have demonstrated abnormalities in the bones of children with NS 
treated with steroids, including increased focal osteomalacia and bone resorption relative to 
controls [30]. Recently, Choudhary et al. performed an interventional trial in children with 
new-onset NS, which showed that children with incident disease had abnormalities in bone 
mineral content at 12 weeks, and supplemental calcium and vitamin D were protective 
against these bone abnormalities [24]. Unfortunately, this study did not report on the impact 
supplementation had on 25(OH)D levels. We extend these findings by showing that vitamin 
D supplementation following diagnosis with new-onset NS is protective against lower 
25(OH)D levels at follow-up. This finding persisted irrespective of the definition of 
25(OH)D deficiency utilized and accounting for factors classically associated with low 
25(OH)D levels in healthy children. Our data suggest that vitamin D supplementation may 
decrease the risk of ongoing deficiency. Despite this compelling data, caution must be taken, 
as a number of very important questions remain about supplementation including the 
optimal form, dose, and duration of vitamin D therapy for these children. Interventional 
trials are needed to determine if vitamin supplementation is effective at correcting 
deficiency and improving bone mineral health in children with NS.
In the context of the high rates of 25(OH)D deficiency in children with NS, it is important to 
evaluate the potential mechanisms and biochemical implications for 25(OH)D deficiency. A 
known mechanism for the development of 25(OH)D deficiency is the loss of vitamin D-
binding protein in the urine during the active phase of NS. This is thought to contribute to 
the transient nature of 25(OH)D deficiency previously reported in the literature in children 
with NS. While we did not measure vitamin D-binding protein levels in this study, we did 
evaluate proteinuria and serum albumin levels at follow-up, which we used as surrogates. 
The degree of proteinuria and lower serum albumin did not predict 25(OH)D deficiency at 
follow-up, though the serum albumin level did approach significance. This suggests that the 
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25(OH)D deficiency seen in children with NS at 3 months following diagnosis cannot 
simply be explained by persistent disease activity. In evaluating the impact of 25(OH)D 
deficiency in children with NS, it is important to evaluate the impact on 1, 25(OH)D and 
iPTH levels. An interesting finding in our study was that 35 % of patients had low 
1,25(OH)D levels and 47 % had elevated iPTH levels at baseline, despite a rate of 100 % 
25(OH)D deficiency. At follow-up, we found that of those with 25(OH)D deficiency, 44 % 
had elevated iPTH and there were no abnormalities in 1,25(OH)D levels. These findings are 
consistent with previous reports and extend them by describing this phenomenon in incident 
patients. Furthermore, abnormalities in bone mineralization have been reported in children 
with NS despite “normal” 1,25(OH)D and iPTH levels. In evaluating the correlations 
between 25(OH)D levels and 1,25(OH)D and iPTH, we show that there are no significant 
correlations at baseline or follow-up when the whole cohort is examined, but there are 
divergent correlations when patients are dichotomized by remission status. In children in 
remission at follow-up, there was a marginally significant positive correlation between 
25(OH)D level with 1, 25(OH)D and a negative correlation with iPTH. This is consistent 
with the anticipated physiologic response to improved 25(OH) levels. An interesting finding 
is the positive correlation seen between 25(OH)D and iPTH at follow-up in children in 
relapse, and warrants further evaluation of potential mechanisms. Further studies evaluating 
these parameters and their impact in children with NS are warranted.
In reviewing our study in the context of previous studies and epidemiologic data, there are 
some interesting findings. One such finding is the influence of black race on the rates of 
25(OH)D deficiency. In univariate analysis, black race was shown to be strongly associated 
with 25(OH)D deficiency consistent with NHANES epidemiologic data. However, on linear 
regression analysis, this association did not persist. This may simply reflect the small sample 
size or the importance of other factors outside of race. Another interesting finding is the fact 
that children from “northern” institutions were less likely to have 25(OH)D deficiency. This 
finding is likely representative of the relatively small distance between some of the sites 
(North vs. South) coupled with local practice variations in supplementation. Indeed, larger 
studies are warranted to further clarify the factors that predict 25(OH)D deficiency in these 
patients.
Our study has a number of strengths, such as the inclusion of a large sample of children with 
new-onset idiopathic NS from a geographically diverse patient population across North 
America. To our knowledge, this is the first such longitudinal multicenter study of a North 
American population evaluating vitamin D in children following diagnosis. Furthermore, we 
present data on a racially diverse population that is consistent with the patterns of 
presentation of NS in North American children. The limitations of our study include a short 
observation period of only 3 months, a modest sample size, and inability to assess causal 
relationships between vitamin D supplementation and return to normal 25(OH)D levels, as 
this was an observational study.
Conclusions
We present the largest study to date in North American children with incident idiopathic NS 
evaluating 25(OH)D deficiency and the first study to prospectively follow 25(OH)D levels 
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after diagnosis in this patient population. In this national sample, all children with incident 
NS had 25(OH)D deficiency at diagnosis and the majority continued to have a deficiency at 
2–4 months. Furthermore, supplemental vitamin D decreased the odds of 25(OH)D 
deficiency, suggesting the need for future interventional studies addressing vitamin D 
supplementation in incident NS to evaluate optimal vitamin D dosing and long-term impact 
in these children.
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Table 1
Patient characteristic’s at study baseline
(n=61)
Age (years) 5 (3, 11)
Male (sex) 39 (63.9)
Season
 Winter 21 (34.4)
 Spring 16 (26.2)
 Summer 11 (18.0)
 Fall 13 (21.3)
Race
 Black 23 (37.7)
 White 32 (52.5)
 Other 6 (9.8)
North American location
 North 17 (27.9)
 South 44 (72.1)
Laboratory values
 25-Vitamin D (ng/ml) 9 (7, 11)
 1,25-Vitamin D (pg/ml) (normal 18–72 pg/ml)* 19 (15, 33)
 Intact PTH (pg/ml) (normal 10–65 pg/ml)** 59.0 (46.5, 80.5)
 PO4 (mg/dl) 5.1 (4.4, 5.9)
 Mg (mg/dl) 2.0 (2.0, 2.2)
 Albumin (g/dl) 1.5 (1.1, 1.9)
 Ca (mg/dl) 8.0 (7.7, 8.3)
 Corrected calcium (mg/dl) 9.9 (9.5, 10.4)
 25-Vitamin D<20 (ng/ml) 61 (100)
 25-Vitamin D<30 (ng/ml) 61 (100)
Medication
 Vitamin D supplement (n) 4 (6.6)
 Prednisone (n) 17 (27.8)
Continuous variables reported as median (interquartile range); counts presented as n (%)
*54 patients with measured samples
**60 patients with measured samples
North region includes residence in Michigan, Ohio, Ontario, Iowa, Missouri, and Utah
South region includes residence in North Carolina, South Carolina, Kentucky, Georgia, and Louisiana
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Table 2
Patients with a completed follow-up visit
n=51
Age (years) 5 (3, 11)
Male 34 (66.7)
Time in months since baseline visit 2.6 (2.1, 3.4)
Time of year 2nd visit
 Winter (12/21–3/20) 14 (27.5)
 Spring (3/21–6/20) 13 (25.5)
 Summer (6/21–9/20) 17 (33.3)
 Fall (9/21–12/20) 7 (13.7)
Race
 Black 18 (35.3)
 White 27 (52.9)
 Other 6 (11.8)
North American location
 North 14 (27.5)
 South 37 (72.5)
Patient classification (n=50)
 Steroid responsive 36 (72.5)
 Steroid resistant 14 (27.5)
Laboratory values at second visit
 25-Vitamin D (ng/ml 19 (10, 25)
 1,25-Vitamin D (pg/ml (normal 18–72 pg/ml)* 48.5 (35, 69)
 Intact PTH (pg/ml (normal 10–65 pg/ml)** 42.5 (30.0, 71.0)
 PO4 (mg/dl) 5.0 (4.3, 5.5)
 Mg (mg/dl) 2.1 (1.9, 2.2)
 Albumin (g/dl) 3.8 (2.9, 4.3)
 Ca (mg/dl) 9.4 (8.9, 9.9)
 Corrected calcium (mg/dl) 9.7 (9.4, 9.9)
 25-Vitamin D<20 (ng/ml) 27 (52.9)
 25-Vitamin D<30 (ng/ml) 43 (84.3)
Medication
 Vitamin D supplement (n) 17 (33.3)
Continuous variables reported as median (interquartile range); Counts presented as n (%)
*46 patients with measured samples
**50 patients with measured samples
North region includes residence in Michigan, Ohio, Ontario, Iowa, Missouri, and Utah
South region includes residence in North Carolina, South Carolina, Kentucky, Georgia, and Louisiana
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